HIV/AIDS Associated Lymphoma: Review

References

• Global HIV & AIDS statistics −2021 fact sheet. Available from: https://www.unaids.org/en/resources/fact-sheet. Accessed July 29, 2021.
   Google Scholar
• Landgren O, Goedert JJ, Rabkin CS, et al. Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol. 2010;28(5):773. doi:10.1200/JCO.2009.25.1322
   PubMed Web of Science ®Google Scholar
• Cesarman E. Pathology of lymphoma in HIV. Curr Opin Oncol. 2013;25(5):487. doi:10.1097/01.cco.0000432525.70099.a4
   PubMed Web of Science ®Google Scholar
• Wu D, Chen C, Zhang M, et al. The clinical features and prognosis of 100 AIDS-related lymphoma cases. Sci Rep. 2019;9(1):1–7. doi:10.1038/s41598-018-37186-2
   PubMed Web of Science ®Google Scholar
• Re A, Cattaneo C, Rossi G. HIV and lymphoma: from epidemiology to clinical management. Mediterr J Hematol Infect Dis. 2019;11(1). doi:10.4084/mjhid.2019.004
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Wilson WH. How I treat HIV-associated lymphoma. Am J Hematol. 2012;119(14):3245–3255.
   Google Scholar
• Grulich AE, Vajdic CM. The epidemiology of cancers in human immunodeficiency virus infection and after organ transplantation. In: Semin Oncol. Elsevier; 2015.
   Google Scholar
• Dolcetti R, Gloghini A, Caruso A, Carbone A. A lymphomagenic role for HIV beyond immune suppression? Am J Hematol. 2016;127(11):1403–1409.
   Google Scholar
• Carroll V, Garzino-Demo A, Bavoil P. HIV-associated lymphoma in the era of combination antiretroviral therapy: shifting the immunological landscape. Pathog Dis. 2015;73(7):ftv044. doi:10.1093/femspd/ftv044
   PubMed Web of Science ®Google Scholar
• Brunnberg U, Hentrich M, Hoffmann C, Wolf T, Huebel K. HIV-associated malignant lymphoma. Oncol Res Treat. 2017;40(3):82–87. doi:10.1159/000456036
   PubMed Web of Science ®Google Scholar
• Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018;68(2):116–132. doi:10.3322/caac.21438
   PubMed Web of Science ®Google Scholar
• Silas OA, Achenbach CJ, Hou L, et al. Outcome of HIV-associated lymphoma in a resource-limited setting of Jos, Nigeria. Infect Agent Cancer. 2017;12(1):1–7.
   PubMedGoogle Scholar
• Breen EC, Hussain SK, Magpantay L, et al. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS–associated non-Hodgkin B-cell lymphoma. Cancer Epidemiol Biomark Prev. 2011;20(7):1303–1314. doi:10.1158/1055-9965.EPI-11-0037
   PubMed Web of Science ®Google Scholar
• Barta SK, Joshi J, Mounier N, et al. Central nervous system involvement in AIDS‐related lymphomas. Br J Haematol. 2016;173(6):857–866. doi:10.1111/bjh.13998
   PubMed Web of Science ®Google Scholar
• Mwamba PM, Mwanda WO, Busakhala NW, Strother RM, Loehrer PJ, Remick SC. AIDS-related non-Hodgkin’s lymphoma in sub-Saharan Africa: current status and realities of therapeutic approach. Lymphoma. 2012;2012:1–9. doi:10.1155/2012/904367
   Google Scholar
• Riedel DJ, Rositch AF, Redfield RR, Blattner WA. HIV-associated lymphoma sub-type distribution, immunophenotypes and survival in an urban clinic population. Leuk Lymphoma. 2016;57(2):306–312. doi:10.3109/10428194.2015.1055483
   PubMed Web of Science ®Google Scholar
• Gloghini A, Dolcetti R, Carbone A. Lymphomas occurring specifically in HIV-infected patients: from pathogenesis to pathology. In: Semin Cancer Biol. Elsevier; 2013.
   Google Scholar
• Noy A. Optimizing treatment of HIV-associated lymphoma. Am J Hematol. 2019;134(17):1385–1394.
   Google Scholar
• Jacobson CA, Abramson JS. HIV-associated Hodgkin’s lymphoma: prognosis and therapy in the era of cART. Adv Hematol. 2012;2012:1–8. doi:10.1155/2012/507257
   Google Scholar
• Xie Y, Pittaluga S, Jaffe ES. The histological classification of diffuse large B-cell lymphomas. In: Semin Hematol. Elsevier; 2015.
   Google Scholar
• Magangane PS, Mohamed Z, Naidoo R. Diffuse large B-cell lymphoma in a high human immunodeficiency virus (HIV) prevalence, low-resource setting. J Oncol. 2020;4(1):1–7.
   Google Scholar
• Meister A, Hentrich M, Wyen C, Hübel K. Malignant lymphoma in the HIV‐positive patient. Eur J Haematol. 2018;101(1):119–126. doi:10.1111/ejh.13082
   PubMed Web of Science ®Google Scholar
• Shah HJ, Keraliya AR, Jagannathan JP, Tirumani SH, Lele VR, DiPiro PJ. Diffuse large B-cell lymphoma in the era of precision oncology: how imaging is helpful. Korean J Radiol. 2017;18(1):54–70. doi:10.3348/kjr.2017.18.1.54
   PubMed Web of Science ®Google Scholar
• Grogg K, Miller R, Dogan A. HIV infection and lymphoma. J Clin Pathol. 2007;60(12):1365–1372. doi:10.1136/jcp.2007.051953
   PubMed Web of Science ®Google Scholar
• Besson C, Lancar R, Prevot S, et al. Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era. AIDS. 2017;31(18):2493–2501. doi:10.1097/QAD.0000000000001652
   PubMed Web of Science ®Google Scholar
• Pinisetti S, Nalabolu GRK, Chowdary U, Tadi DP. HIV associated intra–oral Burkitt’s lymphoma: a case report. J Clin Diagn Res. 2013;7(12):3088. doi:10.7860/JCDR/2013/6715.3862
   PubMedGoogle Scholar
• WebMD. Burkitt lymphoma. Available from: https://www.webmd.com/cancer/lymphoma/burkitt-lymphoma-prognosis-diagnosis-treatments#1. Accessed October 9, 2021.
   Google Scholar
• Corti M. Burkitt’s lymphoma associated with HIV infection. Clin Microbiol. 2016;5(01):2. doi:10.4172/2327-5073.1000232
   Google Scholar
• Dozzo M, Carobolante F, Donisi PM, et al. Burkitt lymphoma in adolescents and young adults: management challenges. Adolesc Health Med Ther. 2017;8:11. doi:10.2147/AHMT.S94170
   PubMed Web of Science ®Google Scholar
• Klapproth K, Wirth T. Advances in the understanding of MYC‐induced lymphomagenesis. Br J Haematol. 2010;149(4):484–497. doi:10.1111/j.1365-2141.2010.08159.x
   PubMed Web of Science ®Google Scholar
• Grommes C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol. 2017;35(21):2410. doi:10.1200/JCO.2017.72.7602
   PubMed Web of Science ®Google Scholar
• Zhao H, Ma M, Zhang L, et al. Diagnosis of central nervous system lymphoma via cerebrospinal fluid cytology: a case report. BMC Neurol. 2019;19(1):1–6. doi:10.1186/s12883-019-1317-3
   PubMed Web of Science ®Google Scholar
• Bayraktar S, Bayraktar UD, Ramos JC, Stefanovic A, Lossos IS. Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors. J Neurooncol. 2011;101(2):257–265. doi:10.1007/s11060-010-0252-3
   PubMed Web of Science ®Google Scholar
• Jarrett RF. Viruses and lymphoma/leukaemia. J Pathol. 2006;208(2):176–186. doi:10.1002/path.1905
   PubMed Web of Science ®Google Scholar
• Antar A, El Hajj H, Jabbour M, et al. Primary effusion lymphoma in an elderly patient effectively treated by lenalidomide: case report and review of literature. Blood Cancer J. 2014;4(3):e190–e. doi:10.1038/bcj.2014.6
   PubMed Web of Science ®Google Scholar
• Narkhede M, Arora S, Ujjani C. Primary effusion lymphoma: current perspectives. Onco Targets Ther. 2018;11:3747. doi:10.2147/OTT.S167392
   PubMed Web of Science ®Google Scholar
• Campogiani L, Cerva C, Maffongelli G, et al. Remission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravir. AIDS Res Ther. 2019;16(1):1–7. doi:10.1186/s12981-019-0230-6
   PubMed Web of Science ®Google Scholar
• Kaplan LD. Human herpesvirus-8: Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma. Hematology Am Soc Hematol Educ Program. 2013;2013(1):103–108. doi:10.1182/asheducation-2013.1.103
   PubMed Web of Science ®Google Scholar
• Shimada K, Hayakawa F, Kiyoi H. Biology and management of primary effusion lymphoma. Blood. 2018;132(18):1879–1888. doi:10.1182/blood-2018-03-791426
   PubMed Web of Science ®Google Scholar
• Little RF, Pittaluga S, Dunleavy K. Presentation and pathogenesis of b-cell lymphoid cancers associated with HIV infection. In: Cancers in People with HIV and AIDS. Springer; 2014:155–173.
   Google Scholar
• Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Am J Hematol. 2015;125(15):2323–2330.
   Google Scholar
• Elyamany G, Al Mussaed E, Alzahrani AM. Plasmablastic lymphoma: a review of current knowledge and future directions. Adv Hematol. 2015;2015:1–11. doi:10.1155/2015/315289
   Google Scholar
• Broccoli A, Nanni L, Stefoni V, et al. A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report. BMC Cancer. 2018;18(1):1–5. doi:10.1186/s12885-018-4561-9
   PubMed Web of Science ®Google Scholar
• Lopez A, Abrisqueta P. Plasmablastic lymphoma: current perspectives. Blood Lymphat Cancer. 2018;8:63. doi:10.2147/BLCTT.S142814
   PubMed Web of Science ®Google Scholar
• Bibas M, Castillo JJ. Current knowledge on HIV-associated plasmablastic lymphoma. Mediterr J Hematol Infect Dis. 2014;6(1):e2014064. doi:10.4084/mjhid.2014.064
   PubMedGoogle Scholar
• Yotsumoto M, Ito Y, Hagiwara S, et al. HIV positivity may not have a negative impact on survival in Epstein‑Barr virus‑positive Hodgkin lymphoma: a Japanese nationwide retrospective survey. Oncol Lett. 2018;16(3):3923–3928. doi:10.3892/ol.2018.9132
   PubMed Web of Science ®Google Scholar
• Ul-Haq I, Dalla Pria A, Suardi E, et al. Blood Epstein–Barr virus DNA does not predict outcome in advanced HIV-associated Hodgkin lymphoma. Med Oncol. 2018;35(4):1–4. doi:10.1007/s12032-018-1099-2
   Web of Science ®Google Scholar
• Olszewski AJ, Fallah J, Castillo JJ. Human immunodeficiency virus‐associated lymphomas in the antiretroviral therapy era: analysis of the National Cancer Data Base. Cancer. 2016;122(17):2689–2697. doi:10.1002/cncr.30112
   PubMed Web of Science ®Google Scholar
• Spina M, Carbone A, Gloghini A, Serraino D, Berretta M, Tirelli U. Hodgkin’s disease in patients with HIV infection. Adv Hematol. 2011;2011:1–7. doi:10.1155/2011/402682
   Google Scholar
• Swart L, Novitzky N, Mohamed Z, Opie J. Hodgkin lymphoma at Groote Schuur Hospital, South Africa: the effect of HIV and bone marrow infiltration. Ann Hematol. 2019;98(2):381–389. doi:10.1007/s00277-018-3533-0
   PubMed Web of Science ®Google Scholar
• Carbone A, Volpi CC, Gualeni AV, Gloghini A. Epstein–Barr virus associated lymphomas in people with HIV. Curr Opin HIV AIDS. 2017;12(1):39–46. doi:10.1097/COH.0000000000000333
   PubMed Web of Science ®Google Scholar
• Carbone A, Gloghini A, Caruso A, De Paoli P, Dolcetti R. The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis. Int J Cancer. 2017;140(6):1233–1245. doi:10.1002/ijc.30473
   PubMed Web of Science ®Google Scholar
• Uldrick TS, Little RF. How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus. Am J Hematol. 2015;125(8):1226–1235.
   Google Scholar
• Yarchoan R, Uldrick TS. HIV-associated cancers and related diseases. N Engl J Med. 2018;378(11):1029–1041. doi:10.1056/NEJMra1615896
   PubMed Web of Science ®Google Scholar
• Bertuzzi C, Sabattini E, Bacci F, Agostinelli C, Ferri GG. Two different extranodal lymphomas in an HIV+ patient: a case report and review of the literature. Case Rep Hematol. 2019;2019. doi:10.1155/2019/8959145
   PubMed Web of Science ®Google Scholar
• Bibas M, Antinori A. EBV and HIV-related lymphoma. Mediterr J Hematol Infect Dis. 2009;1(2). doi:10.4084/MJHID.2009.032
   PubMedGoogle Scholar
• Dolcetti R, Giagulli C, He W, et al. Role of HIV-1 matrix protein p17 variants in lymphoma pathogenesis. Proc Natl Acad Sci U S A. 2015;112(46):14331–14336. doi:10.1073/pnas.1514748112
   PubMed Web of Science ®Google Scholar
• da Silva SR, de Oliveira DE. HIV, EBV and KSHV: viral cooperation in the pathogenesis of human malignancies. Cancer Lett. 2011;305(2):175–185. doi:10.1016/j.canlet.2011.02.007
   PubMed Web of Science ®Google Scholar
• Shannon-Lowe C, Rickinson A, Bell A. Epstein-Barr virus-associated lymphomas, philosophical transactions of the Royal Society of London. Series B Biol Sci. 2017;372:20160271. doi:10.1098/rstb.2016.0271
   Web of Science ®Google Scholar
• Shindiapina P, Ahmed EH, Mozhenkova A, Abebe T, Baiocchi RA. Immunology of EBV-related lymphoproliferative disease in HIV-positive individuals. Front Oncol. 2020;10:1723.
   PubMed Web of Science ®Google Scholar
• Sinha S, Agarwal A, Gupta K, et al. Prevalence of HIV in patients with malignancy and of malignancy in HIV patients in a tertiary care center from North India. Curr HIV Res. 2018;16(4):315–320. doi:10.2174/1570162X16666181018161616
   PubMed Web of Science ®Google Scholar
• Hernández-Walias FJ, Vázquez E, Pacheco Y, et al. Risk, diagnostic and predictor factors for classical Hodgkin lymphoma in HIV-1-infected individuals: role of plasma exosome-derived MiR-20a and MiR-21. J Clin Med. 2020;9(3):760. doi:10.3390/jcm9030760
   PubMed Web of Science ®Google Scholar
• Carbone A, Gloghini A, Dotti G. EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist. 2008;13(5):577–585. doi:10.1634/theoncologist.2008-0036
   PubMed Web of Science ®Google Scholar
• Diamond C, Taylor TH, Aboumrad T, Anton‐Culver H. Changes in acquired immunodeficiency syndrome‐related non‐Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. Cancer. 2006;106(1):128–135. doi:10.1002/cncr.21562
   PubMed Web of Science ®Google Scholar
• Kirk O, Pedersen C, Cozzi-Lepri A, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Adv Hematol. 2001;98(12):3406–3412.
   Google Scholar
• Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Adv Hematol. 2001;98(8):2339–2344.
   Google Scholar
• Biggar RJ, Jaffe ES, Goedert JJ, et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood. 2006;108(12):3786–3791. doi:10.1182/blood-2006-05-024109
   PubMed Web of Science ®Google Scholar
• Cobucci RNO, Lima PH, De Souza PC, et al. Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV/AIDS: a systematic review. J Infect Public Health. 2015;8(1):1–10. doi:10.1016/j.jiph.2014.08.003
   PubMed Web of Science ®Google Scholar
• Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97(6):425–432. doi:10.1093/jnci/dji072
   PubMed Web of Science ®Google Scholar
• Herida M, Mary-Krause M, Kaphan R, et al. Incidence of non–AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus–infected patients. J Clin Oncol. 2003;21(18):3447–3453. doi:10.1200/JCO.2003.01.096
   PubMed Web of Science ®Google Scholar
• Franceschi S, Lise M, Clifford G, et al. Changing patterns of cancer incidence in the early-and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer. 2010;103(3):416–422. doi:10.1038/sj.bjc.6605756
   PubMed Web of Science ®Google Scholar
• Yang J, Su S, Zhao H, et al. Prevalence and mortality of cancer among HIV-infected inpatients in Beijing, China. BMC Infect Dis. 2016;16(1):1–7. doi:10.1186/s12879-016-1416-3
   PubMed Web of Science ®Google Scholar
• Goedert JJ, Hosgood HD, Biggar RJ, Strickler HD, Rabkin CS. Screening for cancer in persons living with HIV infection. Trends Cancer. 2016;2(8):416–428. doi:10.1016/j.trecan.2016.06.007
   PubMed Web of Science ®Google Scholar
• Younes A. Handbook of Lymphoma. Springer; 2016.
   Google Scholar
• Tilly H, Da Silva MG, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v116–v25. doi:10.1093/annonc/mdv304
   PubMed Web of Science ®Google Scholar
• Wang HW, Balakrishna JP, Pittaluga S, Jaffe ES. Diagnosis of Hodgkin lymphoma in the modern era. Br J Haematol. 2019;184(1):45–59. doi:10.1111/bjh.15614
   PubMed Web of Science ®Google Scholar
• Harmon CM, Smith LB. Plasmablastic lymphoma: a review of clinicopathologic features and differential diagnosis. Arch Pathol Lab Med. 2016;140(10):1074–1078. doi:10.5858/arpa.2016-0232-RA
   PubMed Web of Science ®Google Scholar
• Wang D, Zheng Y, Zeng D, et al. Clinicopathologic characteristics of HIV/AIDS-related plasmablastic lymphoma. Int J STD AIDS. 2017;28(4):380–388. doi:10.1177/0956462416650124
   PubMed Web of Science ®Google Scholar
• Castelli R, Schiavon R, Preti C, Ferraris L. HIV-related lymphoproliferative diseases in the era of combination antiretroviral therapy. Cardiovasc Hematol Disord Drug Targets. 2020;20(3):175–180. doi:10.2174/1871529X20666200415121009
   PubMedGoogle Scholar
• Barta SK, Xue X, Wang D, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013;122(19):3251–3262. doi:10.1182/blood-2013-04-498964
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhang R, Liu L, et al. Incidence and spectrum of infections among HIV/AIDS patients with lymphoma during chemotherapy. J Infect Chemother. 2021;27(10):1459–1464. doi:10.1016/j.jiac.2021.06.012
   PubMed Web of Science ®Google Scholar
• Pongas GN, Ramos JC. HIV-associated lymphomas: progress and new challenges. J Clin Med. 2022;11(5):1447. doi:10.3390/jcm11051447
   PubMed Web of Science ®Google Scholar
• Sparano JA, Lee S, Chen MG, et al. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin’s lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). Clin Oncol. 2004;22(8):1491–1500.
   Web of Science ®Google Scholar
• Wu J, Miao Y, Qian C, et al. Clinical characteristics and outcomes in HIV-associated diffuse large B-cell lymphoma in China: a retrospective single-center study. J Cancer. 2021;12(10):2903. doi:10.7150/jca.51027
   PubMed Web of Science ®Google Scholar
• Roschewski M. Preventing central nervous system spread in diffuse large B-cell lymphoma–novel approaches needed. Haematologica. 2021;106(9):2298. doi:10.3324/haematol.2021.278559
   PubMed Web of Science ®Google Scholar
• McKay P, Wilson MR, Chaganti S, et al. The prevention of central nervous system relapse in diffuse large B‐cell lymphoma: a British Society for Haematology Good Practice Paper. Br J Haematol. 2020;190(5):708–714. doi:10.1111/bjh.16866
   PubMed Web of Science ®Google Scholar
• Noy A, Lee JY, Cesarman E, et al. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. Blood. 2015;126(2):160–166. doi:10.1182/blood-2015-01-623900
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med. 2013;369(20):1915–1925. doi:10.1056/NEJMoa1308392
   PubMed Web of Science ®Google Scholar
• Ribrag V, Koscielny S, Bosq J, et al. Rituximab and dose-dense chemotherapy for adults with Burkitt’s lymphoma: a randomised, controlled, open-label, Phase 3 trial. Lancet. 2016;387(10036):2402–2411. doi:10.1016/S0140-6736(15)01317-3
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Winer ES, Stachurski D, et al. Prognostic factors in chemotherapy-treated patients with HIV-associated plasmablastic lymphoma. Oncologist. 2010;15(3):293–299. doi:10.1634/theoncologist.2009-0304
   PubMed Web of Science ®Google Scholar
• Gathers DA, Galloway E, Kelemen K, Rosenthal A, Gibson SE, Munoz J. Primary effusion lymphoma: a clinicopathologic perspective. Cancers. 2022;14(3):722. doi:10.3390/cancers14030722
   PubMed Web of Science ®Google Scholar
• Yap DRY, Tan GF, Chang EWY, et al. Clinical features of plasmablastic lymphoma: case series from an asian tertiary cancer center and literature review. J Hematol. 2020;9(3):71. doi:10.14740/jh672
   PubMed Web of Science ®Google Scholar
• Lurain K, Uldrick TS, Ramaswami R, et al. Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate. Blood. 2020;136(19):2229–2232. doi:10.1182/blood.2020006048
   PubMed Web of Science ®Google Scholar